Novartis to license mRNA technology from China's Abogen in a deal worth up to $7.8 billion

Swiss pharmaceutical company Novartis has entered into a licensing agreement with the Chinese biotechnology firm Abogen Biosciences. The deal, which focuses on the development of messenger RNA (mRNA) technology, is valued at up to $7.8 billion.

Under the terms of the agreement, Novartis will gain access to specific mRNA-based assets developed by Abogen. The partnership is structured to include an upfront payment, though the specific financial breakdown of the total $7.8 billion figure has not been publicly detailed. The remaining value of the deal is contingent upon the successful achievement of various development, regulatory, and commercial milestones.

This collaboration marks a significant expansion of Novartis’s efforts in the mRNA space. By licensing these assets, the company aims to bolster its pipeline and leverage new technologies to address medical needs. The agreement highlights the growing interest among global pharmaceutical companies in Chinese biotech innovation, particularly in the field of mRNA, which gained widespread prominence during the development of COVID-19 vaccines.

Abogen, based in Suzhou, China, specializes in the research and development of mRNA therapeutics and vaccines. The company has been working to advance its proprietary delivery systems and platform technology. This partnership provides Abogen with a major international collaborator to help bring its research to a global market.

Both companies have confirmed the financial scale of the agreement, with the total potential value reaching approximately $7.8 billion. The deal represents one of the larger licensing arrangements between a multinational pharmaceutical firm and a Chinese biotech entity in recent years, reflecting ongoing investment in mRNA research and development.